Daraxonrasib: Harapan Baru dari Medan Perang Melawan Kanker Pankreas yang Paling Ditakuti
Daraxonrasib adalah obat baru yang menjanjikan untuk kanker pankreas, yang terkenal sulit diobati. Obat ini menunjukkan efektivitas dalam uji klinis fase 3, memperbaiki kelangsungan hidup pasien dengan mutasi RAS dibandingkan kemoterapi standar. Data keberhasilannya menggembirakan, menawarkan harapan baru bagi pasien yang sebelumnya memiliki pilihan terbatas.
“Any attempt to sideline or bypass our member First Nations will not only jeopardize project success but also undermine the legitimacy of the development process itself.”
#Indigenous #FirstNations #PDAC #mining #ONpoli #cdnpoli #investment
To the investors, mining companies, government representatives, and stakeholders gathered at the Prospectors & Developers Association of Canada(PDAC) Conference in Toronto, the Anishinabek Nation, which supports and advocates for 39 member First Nations across Ontario, wishes to be clear: true certainty in critical minerals development can only be achieved through genuine, equitable partnership with our nations.
What a break-through!
Spanish scientists completely cure pancreatic cancer (PDAC) in mice.
The group focused on KRAS, a gene mutated in 90% of people with pancreatic cancer. The team employed a triple therapy, which combined an experimental KRAS inhibitor (daraxonrasib) with an approved drug for certain lung adenocarcinomas (afatinib) and a protein degrader (SD36).
#PDAC #PancreaticCancer #Science #Medicine #Oncology #CancerTreatment
In Spain, more than 10,300 cases of pancreatic cancer are diagnosed each year, making it one of the most aggressive forms of cancer. Its detection in the late stages of the disease and the lack of effective therapies mean that the five-year survival rate after diagnosis is less than 10%. But research is finally taking […]
After three intensive days of scientific excellence, our course has come to an end. It has been an honor to have such committed and passionate students participating in pancreatic ductal adenocarcinoma (PDAC) research. Thank you to all our students for making this course a resounding success!
See you at the next edition!
#PancreaticCancer #Oncology #MedicalResearch #PDAC #SummerCourse
@Impossible_PhD I remember reading about Pfizer/BioNTech clinical trials for mRNA vaxx PDAC treatment in 2023, shortly after my mom was diagnosed.
This is immensely important and a huge breakthrough.
Extraordinary work by both BioNTech and MSKCC researchers.
https://www.mskcc.org/clinical-updates/custom-mrna-vaccines-pancreatic
We’re excited to share our latest research: “ELOVL6 as a Therapeutic Target: Disrupting c-MYC-Driven Lipid Metabolism to Enhance Chemotherapy in Pancreatic Cancer.”
https://www.biorxiv.org/content/10.1101/2024.11.11.622928v1
Targeting metabolic dependencies like ELOVL6 in c-MYC-driven cancers could open new avenues in PDAC treatment, offering hope for better patient outcomes. Follow us for updates as we continue exploring the therapeutic potential of lipid metabolism in cancer
The intratumor microbiota in pancreatic cancer has been described as pro-tumorigenic. Here the authors modify the probiotic Lactobacillus rhamnosus GG with a gallium-polyphenol network and chitosan nanocoating, showing accumulation in pancreatic lesions and modulation of the intratumor microbiota, eliciting anti-tumor immune response in preclinical models.
Bhyllabus l'énigme
Windspeaker.com
The Polish Dispatch
EssJay PURPLE PURPOSE
victorjavierlo